PHILIPS NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139 BRL | 0.00% |
|
0.00% | +24.77% |
| Jul. 09 | PHILIPS NV : Gets a Neutral rating from JP Morgan | ZD |
| Jul. 08 | European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 168.46 and 20.08 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +24.77% | 24.12B | - | ||
| +4.64% | 212B | B | ||
| +8.99% | 187B | B- | ||
| +29.83% | 155B | B- | ||
| +35.17% | 115B | A- | ||
| +2.55% | 65.5B | A- | ||
| +15.06% | 52.87B | B+ | ||
| -6.47% | 45.25B | B+ | ||
| -2.14% | 39.7B | A | ||
| +6.88% | 37.72B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PHIA Stock
- PHGN34 Stock
- Ratings Philips NV
